Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Long-Term Deferred Tax of $59.4 million for Q4 2025, up 94.19% year-over-year from $30.6 million in Q4 2024, and up 94.19% quarter-over-quarter from $30.6 million in Q4 2024.
Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Long-Term Deferred Tax for 3 consecutive years, with $59.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 94.19% year-over-year to $59.4 million; the TTM figure through Dec 2025 stood at $59.4 million (up 94.19% YoY), while the FY2025 annual figure was $59.4 million, up 105.23% from the prior year.
- Long-Term Deferred Tax advanced to $59.4 million in Q4 2025 per TLX's latest filing, from $30.6 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $59.4 million in Q4 2025 and bottomed at $13.3 million in Q4 2023.
- Historically, Long-Term Deferred Tax has averaged $34.4 million across 3 years, with a median of $30.6 million in 2024.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax surged 129.56% — and 2025, when it surged 94.19%.
- Telix Pharmaceuticals' Long-Term Deferred Tax stood at $13.3 million in 2023, then soared by 129.56% to $30.6 million in 2024, then jumped by 94.19% to $59.4 million in 2025.
- Business Quant data shows TLX's Long-Term Deferred Tax at $59.4 million in Q4 2025, $30.6 million in Q4 2024, and $13.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59.35 Mn |
| Dec 31, 2024 | 30.56 Mn |
| Dec 31, 2023 | 13.31 Mn |